Ken Griffin Viridian Therapeutics, Inc.\De Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$12.16 - $23.33 $37,696 - $72,323	-3,100 Reduced 9.9%	28,200 $641,000
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.26 $13,920 - $20,712	1,200 Added 3.99%	31,300 $407,000
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $162,355 - $226,290	9,500 Added 46.12%	30,100 $527,000
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $189,040 - $382,500	17,000 Added 472.22%	20,600 $448,000
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $178,888 - $291,460	-11,800 Reduced 76.62%	3,600 $55,000
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $42,883 - $56,373	1,900 Added 14.07%	15,400 $366,000
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $175,280 - $263,200	-7,000 Reduced 34.15%	13,500 $343,000
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $997,218 - $1.58 Million	-53,100 Reduced 72.15%	20,500 $598,000
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $204,370 - $487,050	-19,100 Reduced 20.6%	73,600 $1.51 Million

178

76.6M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $759M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.